[Asia Economy Reporter Jang Hyowon] EV Suseong announced on the 3rd that its coronavirus prevention spray, 'Covixyl,' has become a bestseller on Walmart's online shopping mall in the United States.


Covixyl is a coronavirus prevention nasal spray developed by Salvacion, an affiliate of EV Suseong. By spraying 2 to 3 times a day, it forms a physical protective barrier in the nasal cavity and blocks the virus from entering the human body. It is the world's first product approved by government agencies as a coronavirus prevention spray.


A company representative explained, "We are actively selling Covixyl throughout the United States through Walmart's online and offline stores," adding, "Recently, with the emergence of variant viruses such as XBB.1.5, there was even a temporary shortage of the product."


The COVID-19 XBB.1.5 variant is one of the latest subvariants of Omicron. It has been rapidly spreading across the northeastern United States recently. According to the U.S. Centers for Disease Control and Prevention (CDC), the confirmed cases of XBB.1.5 were only 0.6% a month ago but surged to 40.5% by the end of last month, quickly becoming the dominant strain.


In particular, this virus is known to have more mutations in the spike protein than other variants. Vaccines are developed based on the spike protein, and the more severe the mutations in the spike protein, the less effective the vaccine is explained to be.


EV Suseong stated, "We are continuing supply contract discussions with companies from various countries, including the United States and China," emphasizing, "We will make every effort to prevent the spread of variant viruses through smooth production and supply of the product."



Meanwhile, Salvacion Investment Association is the largest shareholder holding 11.39% of EV Suseong's shares. EV Suseong will change its trade name to Suseong Salvacion.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing